Vasodilators across the heart failure spectrum: Not all patients, and not all vasodilators, are created equal

Journal of the American College of Cardiology

Volumn 59, Issue 5, 2012, Pages 452-454

  Solomon, Scott D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

heart failure; treatment; vasodilation; ventricular function; ventricular arterial interaction

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CANDESARTAN; ENALAPRIL; HYDRALAZINE PLUS ISOSORBIDE DINITRATE; IRBESARTAN; NITROPRUSSIDE SODIUM; VASODILATOR AGENT;

DRUG DOSE TITRATION; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; HEART AFTERLOAD; HEART CATHETERIZATION; HEART EJECTION FRACTION; HEART FAILURE; HEART FAILURE WITH REDUCED EJECTION FRACTION; HEART HEMODYNAMICS; HEART MUSCLE CONTRACTILITY; HEART OUTPUT; HEART STROKE VOLUME; HEART VENTRICLE FILLING; HUMAN; LUNG WEDGE PRESSURE; NOTE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PULMONARY ARTERY OCCLUSION PRESSURE; SYMPTOM;

EID: 84856180422     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2011.10.870     Document Type: Editorial

References (24)

1. J.N. Cohn, J.A. Franciosa Vasodilator therapy of cardiac failure (first of two parts) N Engl J Med 297 1977 27 31 (Pubitemid 8114597)
2. J.N. Cohn, D.G. Archibald, S. Ziesche Effect of vasodilator therapy on mortality in chronic congestive heart failure Results of a Veterans Administration Cooperative Study N Engl J Med 314 1986 1547 1552 (Pubitemid 16114684)
3. The CONSENSUS Trial Study Group Effects of enalapril on mortality in severe congestive heart failure Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS) N Engl J Med 316 1987 1429 1435
4. The SOLVD Investigators Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure N Engl J Med 325 1991 293 302
5. Heart Failure Society of America HFSA 2006 comprehensive heart failure practice guideline J Card Fail 12 2006 e1 e2
6. G.P. Aurigemma, W.H. Gaasch Clinical practice Diastolic heart failure N Engl J Med 351 2004 1097 1105
7. K. Dickstein, A. Cohen-Solal, G. Filippatos ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2008 of the European Society of Cardiology Eur Heart J 29 2008 2388 2442
8. J.G. Cleland, M. Tendera, J. Adamus, N. Freemantle, L. Polonski, J. Taylor PEP-CHF Investigators The Perindopril in Elderly People With Chronic Heart Failure (PEP-CHF) study Eur Heart J 27 2006 2338 2345 (Pubitemid 44453578)
9. S. Yusuf, M.A. Pfeffer, K. Swedberg CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial Lancet 362 2003 777 781 (Pubitemid 37093918)
10. B.M. Massie, P.E. Carson, J.J. McMurray I-PRESERVE Investigators Irbesartan in Patients With Heart Failure and Preserved Ejection Fraction N Engl J Med 359 2008 2456 2467
11. S. Schwartzenberg, M.M. Redfield, A.M. From, P. Sorajja, R.A. Nishimura, B.A. Borlaug Effects of vasodilation in heart failure with preserved or reduced ejection fraction: implications of distinct pathophysiologies on response to therapy J Am Coll Cardiol 59 2012 442 451
12. R.S. Bhatia, J.V. Tu, D.S. Lee Outcome of heart failure with preserved ejection fraction in a population-based study N Engl J Med 355 2006 260 269 (Pubitemid 44088349)
13. D.S. Lee, P. Gona, R.S. Vasan Relation of disease pathogenesis and risk factors to heart failure with preserved or reduced ejection fraction: insights from the Framingham Heart Study of the National Heart, Lung, and Blood Institute Circulation 119 2009 3070 3077
14. J.J. McMurray, J. Ostergren, K. Swedberg CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function taking angiotensin-converting-enzyme inhibitors: the CHARM-Added trial Lancet 362 2003 767 771 (Pubitemid 37093916)
15. C.B. Granger, J.J. McMurray, S. Yusuf CHARM Investigators and Committees Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial Lancet 362 2003 772 776 (Pubitemid 37093917)
16. B. Dahlof, K. Pennert, L. Hansson Reversal of left ventricular hypertrophy in hypertensive patients A metaanalysis of 109 treatment studies Am J Hypertens 5 1992 95 110
17. C.G. Brilla, R.C. Funck, H. Rupp Lisinopril-mediated regression of myocardial fibrosis in patients with hypertensive heart disease Circulation 102 2000 1388 1393
18. J. Diez, R. Querejeta, B. Lopez Losartan-dependent regression of myocardial fibrosis is associated with reduction of left ventricular chamber stiffness in hypertensive patients Circulation 105 2002 2512 2517 (Pubitemid 34568973)
19. A.S. Desai, E.f. Lewis, R. Li Rationale and design of the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial: a randomized, controlled study of spironolactone in patients with symptomatic heart failure and preserved ejection fraction Am Heart J 162 2012 966 972
20. J.N. Cohn, G. Johnson, S. Ziesche A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure N Engl J Med 325 1991 303 310
21. R. Wachter, S. Schmidt-Schweda, D. Westermann Blunted frequency-dependent upregulation of cardiac output is related to impaired relaxation in diastolic heart failure Eur Heart J 30 2009 3027 3036
22. S.D. Solomon, R. Janardhanan, A. Verma Valsartan in Diastolic Dysfunction (VALIDD) Investigators Effect of angiotensin receptor blockade and antihypertensive drugs on diastolic function in patients with hypertension and diastolic dysfunction: a randomised trial Lancet 369 2007 2079 2087 (Pubitemid 46935945)
23. S.D. Solomon, A. Verma, A. Desai Exforge Intensive Control of Hypertension to Evaluate Efficacy in Diastolic Dysfunction Investigators Effect of intensive versus standard blood pressure lowering on diastolic function in patients with uncontrolled hypertension and diastolic dysfunction Hypertension 55 2010 241 248
24. M.A. Pfeffer, K. Swedberg, C.B. Granger CHARM Investigators and Committees Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme Lancet 362 2003 759 766 (Pubitemid 37093915)